Shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.45.
Several research firms recently issued reports on ARWR. B. Riley raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $18.00 to $19.00 in a research report on Thursday, September 6th. Chardan Capital reissued a “buy” rating and issued a $17.50 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. Cantor Fitzgerald lifted their price target on shares of Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, October 4th. William Blair reissued an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 17th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $25.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 4th.
In related news, CEO Christopher Richard Anzalone sold 81,500 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, November 9th. The shares were sold at an average price of $14.39, for a total value of $1,172,785.00. Following the completion of the sale, the chief executive officer now owns 1,727,755 shares of the company’s stock, valued at approximately $24,862,394.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Peter Brian Leone sold 131,137 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, October 19th. The shares were sold at an average price of $13.49, for a total transaction of $1,769,038.13. Following the completion of the sale, the vice president now directly owns 160,000 shares of the company’s stock, valued at approximately $2,158,400. The disclosure for this sale can be found here. In the last three months, insiders sold 215,637 shares of company stock valued at $2,980,043. 4.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. RTW Investments LP grew its position in Arrowhead Pharmaceuticals by 184.6% in the 2nd quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock valued at $112,874,000 after purchasing an additional 5,382,981 shares during the period. BlackRock Inc. lifted its stake in Arrowhead Pharmaceuticals by 108.1% during the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock valued at $96,342,000 after acquiring an additional 3,679,986 shares in the last quarter. FMR LLC bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at $37,922,000. Northern Trust Corp lifted its stake in Arrowhead Pharmaceuticals by 380.1% during the 2nd quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock valued at $14,464,000 after acquiring an additional 841,982 shares in the last quarter. Finally, First Manhattan Co. lifted its stake in Arrowhead Pharmaceuticals by 11.6% during the 3rd quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock valued at $96,883,000 after acquiring an additional 523,675 shares in the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.
Shares of ARWR stock opened at $13.63 on Friday. The company has a market cap of $1.19 billion, a PE ratio of -29.00 and a beta of 2.05. Arrowhead Pharmaceuticals has a 52 week low of $3.01 and a 52 week high of $22.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.69 and a quick ratio of 8.69.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Recommended Story: Terms to Better Understand Call Options
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.